Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Liver cancer is the fifth most common cancer and the second leading cause of malignant
death in Asia, and Asia reports 72.5% of the world's cases in 2020. As the most common …

Background A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–
associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …

PURPOSE Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular
carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to …

Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …

Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second
leading cause of cancer-related mortality worldwide. This review is an updated version that …

Introduction The combination of lenvatinib, toripalimab and hepatic arterial infusion
chemotherapy (HAIC) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) suggested …

Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
death worldwide. Although biannual ultrasound surveillance with or without α-fetoprotein …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …